MARKET

HOPHF

HOPHF

Hemogenyx Pharma
OTCPK
0.040
NaN%
Closed 09:30 05/15 EDT
OPEN
--
PREV CLOSE
0.040
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.040
52 WEEK LOW
0.040
MARKET CAP
272.00K
P/E (TTM)
-0.0135
1D
5D
1M
3M
1Y
5Y
1D
Hemogenyx signs LOI to explore CAR-T therapy commercialization in Estonia
Seeking Alpha · 09/23/2025 06:47
Weekly Report: what happened at HOPHF last week (0908-0912)?
Weekly Report · 09/15/2025 11:33
Weekly Report: what happened at HOPHF last week (0901-0905)?
Weekly Report · 09/08/2025 11:36
Hemogenyx Pharmaceuticals to issue convertible loan notes
Seeking Alpha · 09/02/2025 08:03
Weekly Report: what happened at HOPHF last week (0825-0829)?
Weekly Report · 09/01/2025 11:30
Weekly Report: what happened at HOPHF last week (0818-0822)?
Weekly Report · 08/25/2025 11:43
Weekly Report: what happened at HOPHF last week (0811-0815)?
Weekly Report · 08/18/2025 11:33
Hemogenyx Pharmaceuticals PLC - Third Patient Treated with HG-CT-1 CAR-T Therapy
Barchart · 08/14/2025 21:00
More
About HOPHF
Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.

Webull offers Hemogenyx Pharmaceuticals PLC stock information, including OTCPK: HOPHF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOPHF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOPHF stock methods without spending real money on the virtual paper trading platform.